SEC Form 4 · accession 0001209191-15-047688

PHARMACYCLICS INC · PCYC

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

David Duane Smith

Director

Period of report

May 26, 2015

Accepted (ET)

May 28, 2015 · 6:49 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000949699

Table I — non-derivative securities

No Table I lines on this filing.

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Stock Option (Right to Buy)^F1	$3.10	May 26, 2015	D	7,258	D	—	Jan 4, 2020	Common Stock	7,258	D
Stock Option (Right to Buy)^F1	$2.90	May 26, 2015	D	7,500	D	—	Dec 17, 2019	Common Stock	7,500	D
Stock Option (Right to Buy)^F1	$6.63	May 26, 2015	D	3,393	D	—	Apr 1, 2020	Common Stock	3,393	D
Stock Option (Right to Buy)^F1	$7.14	May 26, 2015	D	1,100	D	—	Aug 6, 2020	Common Stock	1,100	D
Stock Option (Right to Buy)^F1	$6.75	May 26, 2015	D	3,333	D	—	Jul 1, 2020	Common Stock	3,333	D
Stock Option (Right to Buy)^F1	$8.12	May 26, 2015	D	2,954	D	—	Oct 1, 2020	Common Stock	2,954	D
Stock Option (Right to Buy)^F1	$6.52	May 26, 2015	D	3,680	D	—	Jan 3, 2021	Common Stock	3,680	D
Stock Option (Right to Buy)^F1	$5.76	May 26, 2015	D	7,500	D	—	Dec 9, 2020	Common Stock	7,500	D
Stock Option (Right to Buy)^F1	$6.01	May 26, 2015	D	4,242	D	—	Apr 1, 2021	Common Stock	4,242	D
Stock Option (Right to Buy)^F1	$10.58	May 26, 2015	D	2,409	D	—	Jul 1, 2021	Common Stock	2,409	D
Stock Option (Right to Buy)^F1	$11.31	May 26, 2015	D	2,917	D	—	Oct 3, 2021	Common Stock	2,917	D
Stock Option (Right to Buy)^F1	$14.26	May 26, 2015	D	7,500	D	—	Dec 15, 2021	Common Stock	7,500	D
Stock Option (Right to Buy)^F1	$15.02	May 26, 2015	D	2,480	D	—	Jan 3, 2022	Common Stock	2,480	D
Stock Option (Right to Buy)^F1	$28.47	May 26, 2015	D	1,183	D	—	Apr 2, 2022	Common Stock	1,183	D
Stock Option (Right to Buy)^F1	$59.28	May 26, 2015	D	427	D	—	Jul 2, 2022	Common Stock	427	D
Stock Option (Right to Buy)^F1	$65.56	May 26, 2015	D	431	D	—	Oct 1, 2022	Common Stock	431	D
Stock Option (Right to Buy)^F1	$49.00	May 26, 2015	D	7,500	D	—	Nov 9, 2022	Common Stock	7,500	D
Stock Option (Right to Buy)^F1	$61.44	May 26, 2015	D	413	D	—	Jan 2, 2023	Common Stock	413	D
Stock Option (Right to Buy)^F1	$79.67	May 26, 2015	D	298	D	—	Apr 1, 2023	Common Stock	298	D
Stock Option (Right to Buy)^F1	$74.48	May 26, 2015	D	3,750	D	—	May 9, 2023	Common Stock	3,750	D
Stock Option (Right to Buy)^F1	$85.39	May 26, 2015	D	313	D	—	Jul 1, 2023	Common Stock	313	D
Stock Option (Right to Buy)^F1	$139.89	May 26, 2015	D	200	D	—	Oct 1, 2023	Common Stock	200	D
Stock Option (Right to Buy)^F1	$108.44	May 26, 2015	D	217	D	—	Jan 2, 2024	Common Stock	217	D
Stock Option (Right to Buy)^F1	$107.42	May 26, 2015	D	233	D	—	Apr 1, 2024	Common Stock	233	D
Stock Option (Right to Buy)^F1	$95.08	May 26, 2015	D	3,750	D	—	May 9, 2024	Common Stock	3,750	D
Stock Option (Right to Buy)^F1	$89.58	May 26, 2015	D	416	D	—	Jul 1, 2024	Common Stock	416	D
Stock Option (Right to Buy)^F1	$115.80	May 26, 2015	D	308	D	—	Oct 1, 2024	Common Stock	308	D
Stock Option (Right to Buy)^F1	$124.46	May 26, 2015	D	288	D	—	Jan 2, 2025	Common Stock	288	D
Stock Option (Right to Buy)^F1	$257.015	May 26, 2015	D	166	D	—	Apr 7, 2025	Common Stock	166	D

Explanation of responses

F1Pursuant to terms of the Agreement and Plan of Reorganization (the "Merger Agreement") dated March 4, 2015, by and between the Issuer, AbbVie Inc., a Delaware corporation ("AbbVie"), Oxford Amherst Corporation, a Delaware corporation and a direct wholly owned subsidiary of AbbVie and Oxford Amherst LLC, a Delaware limited liability company and a direct wholly owned subsidiary of AbbVie this option was cancelled in exchange for a cash payment equal to the number of shares subject to the option multiplied by the difference between $261.25 and the exercise price of the option, subject to applicable withholding taxes and pursuant to the procedures set forth in the Merger Agreement.